Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s): AQSZF

Healthcare Biotechnology

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.

TSXV:AQS - Post by User

Aequus Pharmaceuticals Inc

Bullboard Posts

Comment by kuatoliveson Jun 21, 2017 12:04pm

90 Views

Post# 26387936

RE:Advance notice policy: The purpose.

I think it's more to do with the techology than the sales force. Any company can launch a sales force in another country with relatively minimal effort, but getting a product/drug approved is a pain. Mr. Janzen said as much in one of his interviews. Just because you have a sales force in Canada, doesn't mean you can sell non-approved products. When someone purchases AQS, it will be for the approved delivery technologies.

Bullboard Posts

Eminent acquires promising Nevada gold project